NEWS
Inhibition of the Ion Channel TMEM16A With Niclosamide Inhalation Powder Reduces Inflammation, Bronchoconstriction, and Airway Hyperresponsiveness in a Large Animal Model of Asthma
Aeon Respire and its development partners look forward to sharing important data from our lead program, AR-001, this month at the American Thoracic Society 2024 International Conference in San Diego. The findings will be presented on May 21 in a poster titled ‘Inhibition of the Ion Channel TMEM16A With Niclosamide Inhalation Powder Reduces Inflammation, Bronchoconstriction, and Airway Hyperresponsiveness in a Large Animal Model of Asthma’.
Read FullAeon Respire's Patent-Protected AR-001 Inhalation Formulation Achieves Lung Exposure 1000 Times Higher Than Oral Delivery
Aeon Respire is pleased to announce that they’ve completed a pivotal pharmacokinetic (PK) study with inhalation delivery of their lead drug AR-001. Inhaled AR-001 led to 1000 times higher lung exposure than
Read FullAeon Respire Presents at the 2022 Biotechnology Innovation Organization (Bio) Convention
We are pleased to announce that Aeon Respire has been selected to present at the 2022 BIO International Convention in San Diego. Dirk Smith, VP of R&D, will present on Monday June 13th at 3:45 pm.
Read FullScientists Identify the Molecular Binding Site of the Drug Niclosamide on TMEM16 PROTEINS
Scientists at the University of California, San Francisco identify the molecular binding site of niclosamide on TMEM16 by high resolution cryo-electron microscopy.
Read Full
Aeon Respire is Awarded Phase 2 Extension Funding From NIH Fast Track SBIR Award
Aeon Respire has been awarded Phase 2 extension SBIR funding from the NIH. This award was contingent on Aeon Respire successfully completing all required dry powder formulation milestones during the Phase 1 period of the SBIR Fast-Track grant
Read FullAeon Respire & CritiTech Enter into Strategic Partnership
Aeon Respire is pleased to announce that it has entered into a strategic drug development collaboration and licensing agreement with CritiTech Particle Engineering Solutions of Lawrence, Kansas (”CritiTech”).
Read FullDrugs that Inhibit TMEM16 Block COVID-19 Virus
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike protein-induced syncytia formation in the lung leading to lymphocyte depletion and COVID-19 disease pathogenesis. Niclosamide was reported in 2020 by several laboratories as a potent inhibitor of SARS-CoV-2 virus replication.
Read FullEx-Amgen Respiratory Scientists Form New Company
Ex-Amgen leaders in respiratory disease form new company Aeon Respire, Inc., based on their pivotal discovery reported in Frontiers in Pharmacology. They found that the approved drugs niclosamide and nitazoxanide are potent inhibitors of the calcium-activated chloride channel TMEM16A that fully bronchodilate human airways.
Read Full